You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

March 9, 2012

Food Registration with the Thai FDA: Overcoming Pitfalls

Bangkok Post, Corporate Counsellor Column

With its diverse range of consumers seeking both traditional wares and more modern Western-influenced products, Thailand, like Vietnam and many other Asean countries, has become a hugely attractive and a lucrative market for foreign and local food manufacturers alike.

But for foreign companies that want to import products into Thailand, their first interaction with the Thai Food and Drug Administration (FDA) too often ends with a firm rebuttal, as their products are rejected for registration or they face significant delays. This is especially true if the food and drug regulators in the countries they are used to dealing with lack a strong pre-marketing review system but instead rely only on a post-marketing process to protect consumers in the event of product liability lawsuits, such as the US.

Although these FDA obstacles can be frustrating, companies can achieve success by familiarizing themselves with Thai FDA practices and preparing for potential pitfalls.

New Food Ingredients

Prior to starting the registration process for a food product, a company must first determine whether all its ingredients have already been approved by the Thai FDA. An ingredient that is commonly registered in another country may not necessarily have been registered with the FDA.

For new ingredients, the FDA will request additional supporting documents. For example, a product used in food consumption must be able to show a history of use for more than 15 years in a foreign country and/or safety data.

Companies need to make strategic decisions about whether to retain the new food ingredient in a formula. On the one hand, the new ingredient can be helpful in differentiating the product from competitors, but on the other hand companies face an extended registration process when new ingredients are included.

Misclassification of Food

Companies often have a misconception that if their products are classified and registered in a certain category in a country such as Singapore, then they would fall into the same category in Thailand. This is not necessarily the case. Prior to FDA submission, an applicant must be fully aware of: (1) the ingredient list for its products; (2) the source of the ingredients; (3) the manufacturing process; (4) the objectives of use; and (5) the targeted consumer group. These factors will allow the company to:

  • Preliminarily classify the product; and
  • Assist in answering registration questions from the Thai FDA.

Misclassifying the product will delay the registration process, because companies are not permitted to transfer a dossier from one category to another. If a category change needs to be made, then the company must restart the application.

Requirements differ from one category to another. For example, if you misclassify a dietary supplement in the food supplement category, which does not require any analysis, when it is in fact a beverage in a sealed container, then this would mean additional documents and a detailed analysis are required. This causes further delays.

These delays can be avoided by carefully preparing and reviewing product ingredients and information before considering the classification.

Preparing Your Dossier Carefully

Asean lacks a system for harmonization of food products, and thus the product dossier requirements differ between member countries. In addition, some other countries, including the US, do not necessarily issue the same types of documents required by the Thai FDA.

The Thai FDA conducts a careful substantive examination of the documents provided, and any discrepancies will further delay the registration process. Companies should ensure that all documents, as requested by the FDA, are complete and consistent. If some documents are unavailable, then be prepared to provide a suitable response to the FDA.

Health Claims on Labels

The Thai FDA takes a stricter approach to claims on labels than in other countries, including the US. For example, the Thai FDA permits nutrition claims if appropriate analysis is conducted. However, health claims—that is, claims relating to benefits, efficacies and functions of the product—are forbidden.

Foreign companies perceive the Thai FDA interpretation as very strict, as it requires a complete amendment of their labels when they are designed abroad. In some cases, however, it is worth negotiating with the FDA, as its officials are willing to learn from industry specialists. It is important for industries to work closely with the FDA in providing assistance on how to differentiate between health claims, slogans and other advertising statements.

Regional Market

Food manufacturers and importers should no longer view Thailand as a stand-alone market when targeting it for their products, but rather part of the overall Asean Economic Community that is due to take effect in 2015. Using this approach, companies can maximize efficiency by planning to register their products across several Asean countries.

Understanding the mechanisms adopted by local Asean FDAs may appear cumbersome, but with assistance from technical experts any company can enjoy a smooth product launch and reap the considerable benefits offered by the increased integration of Asean markets.

RELATED INSIGHTS​ 

August 10, 2026
On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels. The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period. Implementation of the Nutri-Level Labeling System To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging. The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content. For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml. Minimum Vitamin and Mineral Content Required for Declaration BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING). Vitamins or minerals may only be declared if they are present at a
August 10, 2026
The drug registration process in Vietnam will be simplified, particularly for foreign applicants, following the recent issuance by Vietnam’s Ministry of Health (MOH) of a new circular that is expected to reduce administrative hurdles. Circular No. 32/2026/TT-BYT on the registration of drugs and medicinal ingredients (Circular 32) was issued on July 29, 2026, and will take effect on October 1, 2026, replacing Circular No. 12/2025/TT-BYT. Key provisions of the new circular are discussed below. Five-Year Data Exclusivity and Five-Month Public Disclosure Framework Circular 32 updates data protection guidelines by explicitly referencing Article 128 of the amended Intellectual Property Law, which sets out that new drugs supported by clinical trial data submitted for the first time will be granted a five-year data exclusivity period from the date of the initial marketing authorization (MA) approval. Subsequent applications that rely on the originator’s protected data will not be eligible for approval from the date of submission of the originator’s registration dossier until five years after the first MA is granted. Furthermore, in accordance with the new regulations, the regulatory authority must publicly disclose information on subsequent applications five months before the granting of MA, providing originator companies with an opportunity to exercise and enforce their intellectual property rights. Simplified Requirements for Foreign Legal Documents Circular 32 expands the circumstances under which legal documents issued by foreign authorities are exempt from consular legalization and authenticity verification requirements. Specifically, such documents may be exempt if the Drug Administration of Vietnam (DAV) is able to verify their authenticity directly through official electronic means, including written confirmation or email correspondence sent directly to the MOH by the competent foreign authority, or publicly accessible English-language databases maintained by recognized foreign regulatory authorities. In addition, the new circular permits the submission of electronic notarized copies of legal documents
July 24, 2026
As food innovation continues to accelerate, manufacturers are increasingly introducing ingredients derived from new sources, produced using novel technologies, or lacking a significant history of human consumption. While these innovations create new opportunities for the food industry, they also raise important questions regarding consumer safety. For this reason, many jurisdictions, including Thailand, the European Union, Australia and New Zealand, Canada, and Singapore, require a premarket safety assessment for novel food ingredients before they can be placed on the market. The objective of this assessment is to ensure that each ingredient is safe for its intended use and level of consumption, does not present toxicological, allergenic, microbiological, or nutritional concerns, and will not mislead consumers. Scientific authorities typically evaluate the ingredient’s identity, manufacturing process, composition, specifications, anticipated dietary exposure, toxicological information, nutritional impact, and history of use before determining whether it can be marketed. Against this background, the Thai Food and Drug Administration (FDA) recently took an important step toward improving regulatory transparency by publishing, for the first time, a consolidated public list of substances that have successfully completed the Thai FDA’s safety assessment process, including substances determined to be novel foods and those determined not to fall within the novel food category. The list identifies the approved substances, the corresponding manufacturers or importers, approval dates, and the approved conditions of use. Although the publication does not change the existing legal framework governing novel food approvals, it provides businesses with greater visibility into the Thai FDA’s regulatory precedents and the types of substances that have previously been accepted through the safety assessment process. The full announcement is available on the Thai FDA’s website. As the list is now publicly available, it also provides useful insight into the types of substances that have successfully completed the Thai FDA’s safety assessment process.
July 24, 2026
For businesses in Thailand’s regulated industries, the problem of “too many licenses” is one of the most familiar hurdles to getting a product to market. Take a simple example: importing the materials necessary to sell teriyaki chicken skewers. To legally do this, a business may need approvals from several different agencies—separate permits for the chicken (Department of Livestock Development), the dipping sauce (Thai FDA), the wooden skewers (Department of Forestry), and other ingredients, each under a different authority. This kind of overlap is often cited to argue for a “regulatory guillotine”—a systematic review to cut outdated or duplicative rules that slow investment and business activity. The Facilitation of Licensing and Public Service Consideration Act B.E. 2569 (2026) (Licensing Facilitation Act 2026) is Thailand’s most significant response yet to that concern. This article looks at the Facilitation Act 2026 through a life sciences and regulatory affairs lens—what it may mean for the manufacturers, importers, and distributors of food, drugs, medical devices, cosmetics, and similar products who routinely deal with several regulators to bring a single product to market. The Super License: One Approval Standing in for Many The reform with the clearest potential for regulated-product businesses is the law’s “super license” mechanism, referred to as a “main license” in the statute. Once a business obtains the main license for a regulated activity, it is automatically deemed to hold all related sublicenses issued by other agencies for that same activity, provided the activity has been designated as eligible in the Government Gazette. The Licensing Facilitation Act 2026 also creates a central application center, allowing applicants to submit a single application and pay all relevant fees at one point of contact, with the center routing the application to each agency through a shared information system. The potential benefits of this for businesses